In 1999, etanercept (ETN) became the first anti-tumor necrosis factor (anti-TNF) therapy approved by the Food and Drug Administration (FDA) for polyarticular JIA, and has since been shown to be effective in multiple categories of JIA (reviewed in [3–8]). This evidence concerns the gene TNF and polyarticular juvenile idiopathic arthritis.